DrugPatentWatch Database Preview

Ucb Inc Company Profile

« Back to Dashboard

What is the competitive landscape for UCB INC, and when can generic versions of UCB INC drugs launch?

UCB INC has thirty-nine approved drugs.

There are fifteen US patents protecting UCB INC drugs.

Summary for Ucb Inc

US Patents:	15
Tradenames:	26
Ingredients:	21
NDAs:	39
Drug Master File Entries:	1
Patent Litigation for Ucb Inc:	See patent lawsuits for Ucb Inc

Drugs and US Patents for Ucb Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ucb Inc	NEUPRO	rotigotine	FILM, EXTENDED RELEASE;TRANSDERMAL	021829-006	Apr 2, 2012		RX	Yes	No	8,617,591		Y
Ucb Inc	ALBUTEROL SULFATE	albuterol sulfate	TABLET;ORAL	073120-001	Sep 29, 1992		DISCN	No	No
Ucb Inc	NIRAVAM	alprazolam	TABLET, ORALLY DISINTEGRATING;ORAL	021726-002	Jan 19, 2005		DISCN	Yes	No	6,221,392		Y
Ucb Inc	NEUPRO	rotigotine	FILM, EXTENDED RELEASE;TRANSDERMAL	021829-001	May 9, 2007		RX	Yes	Yes	6,699,498		Y
Ucb Inc	BRIVIACT	brivaracetam	TABLET;ORAL	205836-001	May 12, 2016		RX	Yes	No	6,911,461		Y	Y
Ucb Inc	DIETHYLPROPION HYDROCHLORIDE	diethylpropion hydrochloride	TABLET;ORAL	085544-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Ucb Inc	AMITRIPTYLINE HYDROCHLORIDE	amitriptyline hydrochloride	TABLET;ORAL	085936-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for Ucb Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ucb Inc	UNIRETIC	hydrochlorothiazide; moexipril hydrochloride	TABLET;ORAL	020729-001	Jun 27, 1997	4,344,949
Ucb Inc	NIRAVAM	alprazolam	TABLET, ORALLY DISINTEGRATING;ORAL	021726-003	Jan 19, 2005	6,221,392
Ucb Inc	KEPPRA	levetiracetam	TABLET;ORAL	021035-003	Nov 30, 1999	4,837,223
Ucb Inc	KEPPRA XR	levetiracetam	TABLET, EXTENDED RELEASE;ORAL	022285-001	Sep 12, 2008	4,943,639*PED
Ucb Inc	KEPPRA	levetiracetam	TABLET;ORAL	021035-001	Nov 30, 1999	4,943,639*PED
Ucb Inc	VIMPAT	lacosamide	TABLET;ORAL	022253-002	Oct 28, 2008	5,654,301
Ucb Inc	VIMPAT	lacosamide	TABLET;ORAL	022253-003	Oct 28, 2008	5,654,301

Paragraph IV (Patent) Challenges for UCB INC drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Injection	10 mg/mL, 20 mL		2016-06-30
	Orally Disintegrating Tablets	0.25 mg, 0.5 mg, 1 mg and 2 mg		2005-12-27
	Tablets	1000 mg		2007-01-24
	Tablets	50 mg, 100 mg, 150 mg, and 200 mg		2012-10-29
	Extended-release Tablets	1000 mg		2011-01-07
	Tablets	7.5mg/12.5mg 15 mg/25 mg and 15 mg/12.5 mg		2004-01-15
	Extended-release Transdermal Film	1 mg/24 hr, 2 mg/24 hr, 3 mg/24 hr,4 mg/24 hr,6 mg/24 hr, and 8 mg/24 hr		2013-11-26
	Oral Solution	10 mg/mL		2012-10-29

International Patents for Ucb Inc Drugs

Country	Document Number	Estimated Expiration
Taiwan	200626545
Malaysia	139420
Canada	2396686
South Korea	101016838
Bulgaria	109297
Germany	60304477
Denmark	1524975

Supplementary Protection Certificates for Ucb Inc Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C/GB09/007	United Kingdom		PRODUCT NAME: LACOSAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE FORMS; REGISTERED: UK EU/1/08/470/001 20080829; UK EU/1/08/470/002 20080829; UK EU/1/08/470/003 20080829; UK EU/1/08/470/004 20080829; UK EU/1/08/470/005 20080829; UK EU/1/08/470/006 20080829; UK EU/1/08/470/014 20080829; UK EU/1/08/470/015 20080829; UK EU/1/08/470/016 20080829; UK EU/1/08/470/007 20080829; UK EU/1/08/470/008 20080829; UK EU/1/08/470/009 20080829; UK EU/1/08/470/010 20080829; UK EU/1/08/470/012 20080829; UK EU/1/08/470/013 20080829
C0025	France		PRODUCT NAME: ROTIGOTINE; REGISTRATION NO/DATE: EU/1/05/331/001 20060215
C/GB02/037	United Kingdom		PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
C001/2009	Ireland		SPC001/2009: 20091013, EXPIRES: 20220316
C0009	Belgium		PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
C0006	France		PRODUCT NAME: LACOSAMIDE; REGISTRATION NO/DATE IN FRANCE: EU/1/08/470/001 DU 20080829; REGISTRATION NO/DATE AT EEC: EU/1/08/470/001 DU 20080829
C0012	France		PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Ucb Inc